VMAT for small cell lung cancer

We analyzed tumor and non-tumorous lung tissue of 233 non-small cell lung cancer (NSCLC) patients for the presence of copy number alterations (CNAs) in the MAPK kinase 3 (MKK3)

Our systematic review and meta-analysis provides an overview of all published literature on diagnostic accura- cy, scan efficiency and radiation exposure dose of V-Q

Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells. Joyce JA,

The aim of this study was to investigate S100A4-mediated stimulation of ephrin-A1 and osteopontin in non-small cell lung cancer (NSCLC) cell lines, and to characterize the expression

(2011) A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with

Results: The initial study population included 113 patients with stage IV disease who received active therapy; of these, 23 20% had oligometastatic spread a maximum of 3 metastases to

Prognostic impact of CXCL16 and CXCR6 in non- small cell lung cancer: combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival.. Stromal CD8+

The International Association for the Study of Lung Cancer (IASLC) published an article in 1989 recommending that also contralateral mediastinal, contralateral hilar